Evotec SE American Depositary Shares
EVODividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 22, 2019 | $0.07 | 2019-01-11 | 2019-01-14 |
| December 20, 2018 | $0.05 | 2018-12-12 | 2018-12-13 |
| November 19, 2018 | $0.05 | 2018-11-08 | 2018-11-12 |
| October 18, 2018 | $0.05 | 2018-10-10 | 2018-10-11 |
| September 21, 2018 | $0.05 | 2018-09-13 | 2018-09-14 |
Dividends Summary
- Consistent Payer: Evotec SE American Depositary Shares has rewarded shareholders with 126 dividend payments over the past 11 years.
- Total Returned Value: Investors who held EVO shares during this period received a total of $7.73 per share in dividend income.
- Latest Payout: The most recent dividend of $0.07/share was paid 2734 days ago, on January 22, 2019.
- Yield & Schedule: EVO currently pays dividends monthly with an annual yield of 28.99%.
- Dividend Growth: Since 2008, the dividend payout has grown by 31.1%, from $0.06 to $0.07.
- Dividend Reliability: EVO has maintained or increased its dividend for 19 consecutive payments.
Company News
Gilead Sciences announced a $3.15 billion acquisition of Tubulis GmbH to strengthen its oncology pipeline, adding the promising antibody-drug conjugate TUB-040 for ovarian cancer treatment. The deal includes up to $1.85 billion in contingent milestone payments. This acquisition follows Gilead's March purchase of Ouro Medicines for $1.675 billion,...
Johnson Fistel, PLLP is investigating whether Evotec SE complied with federal securities laws following the company's announcement of its 'Horizon' restructuring initiative on March 10, 2026. The investigation focuses on potential investor losses related to Evotec's financial guidance projecting €700-780 million in revenue and €0-40 million i...
The global antibody optimization service market is projected to grow from USD 1.36 billion in 2024 to USD 2.87 billion by 2033, with a CAGR of 8.81%. Growth is driven by rising prevalence of complex diseases, increased R&D investments in biologics, and advancements in computational modeling and protein engineering technologies.
Amgen acquired Dark Blue Therapeutics for up to $840 million to strengthen its oncology pipeline. Dark Blue's lead candidate DBT 3757 targets acute myeloid leukemia and acute lymphoblastic leukemia. The acquisition complements Amgen's targeted protein degradation research and advances its early-stage cancer medicine strategy.
MUVON Therapeutics announced positive Phase 2 clinical trial results for a novel muscle precursor cell therapy treating stress urinary incontinence, demonstrating high statistical significance and an 87% responder rate. The company also appointed Dr. Christine Günther as Chief Technology Officer to advance their regenerative medicine platform.
